Citius Pharma(CTXR) - 2023 Q4 - Annual Report

● A distribution in connection with or following the spinoff could result in substantial tax liability to us and our stockholders. We are subject to a number of risks common to companies in the pharmaceutical industry including, but not limited to, risks related to the development by us or our competitors of research and development stage products, market acceptance of its products that receive regulatory approval, competition from larger companies, dependence on key personnel, dependence on key suppliers a ...